NCT03378531View on ClinicalTrials.gov

A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 7, 2017

Primary Completion Date

December 15, 2022

Study Completion Date

December 15, 2022

Conditions
Arginase I DeficiencyHyperargininemia
Interventions
DRUG

AEB1102

modified human arginase I

Trial Locations (7)

10029

Icahn School of Medicine at Mount Sinai, New York

32610

University of Florida, Gainesville

75390

UTSW, Dallas

94305

Stanford University School of Medicine, Stanford

M5G 1X8

The Hospital for Sick Children, Toronto

Unknown

Centro Hospitalar S. Joao, Porto

Great Ormond Street Hospital, London

Sponsors
All Listed Sponsors
lead

Aeglea Biotherapeutics

INDUSTRY

NCT03378531 - A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency | Biotech Hunter | Biotech Hunter